Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.
EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment
EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma
EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma
EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma
EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma
EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma
EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
EP: 11.Complying with REMS Training and Documentation Requirements
EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
EP: 13.Unmet Needs in Multiple Myeloma Care
EP: 14.Treatment Sequencing and Combination Therapies for MM
EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM
EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
This is a video synopsis/summary of a Practice Pearls involving Ryan Haumschild, PharmD, MS, MBA; Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.
Perissinotti reviews key adverse events of concern with bispecific antibodies for relapsed/refractory multiple myeloma: cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS) and infections. He explains CRS pathophysiology, clinical grading system, and typical interventions like steroids/tocilizumab for grade 2 or higher CRS. ICANS manifestations are delirium and motor deficits assessed by a standard Immune Effector Cell–Associated Encephalopathyscoring system; steroids are first-line treatment. Finally, Perissinotti notes unique toxicities with talquetamab including skin/eye issues and dysgeusia.
Haumschild highlights the importance of pharmacists helping manage adverse effects through grading; order set optimization enabling consistent, standardized responses; and recognizing unique toxicity profiles. He notes variability across centers in prophylactic approaches, making consensus grading systems valuable. Central roles are also educating patients on expected adverse effects and optimizing supportive care.
Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.
